Skip to main content
. Author manuscript; available in PMC: 2022 Oct 6.
Published in final edited form as: Neuron. 2021 Aug 13;109(19):3104–3118.e6. doi: 10.1016/j.neuron.2021.07.018

Fig. 1: Rnf43 identifies OPCs in human and mouse white matter injury.

Fig. 1:

(A, B) RNF43 protein expression identifies OPCs in MS Active lesions (Active), but expression is not seen in surrounding Normal Appearing white Matter (NAWM) from the same cases. (C, D) RNF43 protein is expressed in OPCs in white matter (WM) in the neonatal human white matter injury HIE but is not seen in grey matter (GM) in those same cases. (E) RNF43 expression in red (white arrowheads) colocalizes with the OPC marker PDGFRα in human HIE WM, but separates from markers of other cell types (unfilled arrowheads) such as astrocytes (GFAP), microglia (IBA1), and also from mature oligodendrocytes (CC1) (quantification in Fig. S1G). (F) Staining for RNF43 protein at the boundary of grey (GM) versus white (WM) matter in human HIE (with boxed enlargements shown in f’ and f’ to the right). (G) Quantification of RNF43+ OPCs in MS active lesions and NAWM (n= 4 cases) and human HIE GM versus WM (n=4 cases). (H, I) Rnf43 expression is not seen in mouse adult uninjured CNS, but is expressed in OPCs during remyelination. (I) Rnf43 protein (red) and YFP (green) in PDGFRα-YFP transgenic mice (in which OPCs are labelled with YFP), showing lack of any Rnf43 expression in uninjured CNS (‘No lesion’), but significant expression in OPCs in a 3dpl corpus callosum lesion following lysolecithin induced demyelination, with quantification in (H)(n=4 animals). See also Fig. S1.